ICL Group Ltd. reported its Q3 2025 financial results with total sales of $1.9 billion, adjusted EBITDA of $398 million, and adjusted diluted EPS of $0.10, reflecting a 6% sales increase year-over-year. The filing includes a strategic focus on maintaining market leadership in specialty crop nutrition and global bromine markets.